Pardes Biosciences, Inc. (PRDS) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Carlsbad, CA, United States. The current CEO is Thomas G. Wiggans.
PRDS has IPO date of 2021-12-27, 57 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $135.19M.
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
